Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells

Wang,Qiong; Zhu,Wenwen; Xiao,Geqiong; Ding,Mengyu; Chang,Jian; Liao,Hui

doi:10.3892/mmr.2020.11176

Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells

Authors:
- Qiong Wang
- Wenwen Zhu
- Geqiong Xiao
- Mengyu Ding
- Jian Chang
- Hui Liao
View Affiliations

Affiliations: Department of Oncology, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang 312000, P.R. China
Published online on: May 22, 2020 https://doi.org/10.3892/mmr.2020.11176
Pages: 810-818
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advanced glycosylation end-product specific receptor (AGER) is a multi-ligand cell surface receptor abnormally expressed in lung cancer, and is a member of the immunoglobulin superfamily. Therefore, this study aimed to explore the effect of AGER on the biological behavior of non‑small cell lung cancer (NSCLC) H1299 cell line. A microarray‑based gene expression profiling analysis of the GSE27262 dataset from the Gene Expression Omnibus (GEO) database was conducted to identify differentially expressed genes, which were verified using The Cancer Genome Atlas (TCGA) database. The expression of AGER in the normal human lung BEAS‑2B cell line and NSCLC H1299 cell line was examined using reverse transcription‑quantitative PCR. Lentiviral interference and overexpression vectors of AGER were constructed and transfected into H1299 cells using Lipofectamine®. AGER expression and biological properties, including cell viability, apoptosis, migration and invasion abilities, in H1299 cells were investigated using MTT, flow cytometry, wound healing and Transwell assays. AGER was expressed at a low level in NSCLC tissues and H1299 cells (P<0.05). Compared with control cells, AGER overexpression cells displayed decreased cell viability, proliferation, migration and invasion abilities, and significantly increased levels of apoptosis. Furthermore, AGER overexpression increased the expression of Bax and decreased the expression of Bcl‑2 in H1299 cells (P<0.05), and AGER knockdown displayed the opposite effects on H1299 cells. Therefore, AGER overexpression decreased the proliferation, invasion and migration abilities of H1299 cells, and increased apoptosis. The present study suggested that AGER might serve as a potential molecular marker for NSCLC.

View Figures

View References

1	Zhang F, Yang R, Zhang G, Cheng R, Bai Y, Zhao H, Lu X, Li H, Chen S, Li J, et al: Anticancer function of alpha-solanine in lung adenocarcinoma cells by inducing microRNA-138 expression. Tumour Biol. 37:6437–6446. 2016. View Article : Google Scholar : PubMed/NCBI
2	Sun B, Liu HF, Ding Y and Li Z: Evaluating the diagnostic and prognostic value of serum miR-770 in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 22:3061–3066. 2018.PubMed/NCBI
3	Shi H, Bi H, Sun X, Dong H, Jiang Y, Mu H, Li W, Liu G, Gao R and Su J: Tubeimoside-1 inhibits the proliferation and metastasis by promoting miR-126-5p expression in non-small cell lung cancer cells. Oncol Lett. 16:3126–3134. 2018.PubMed/NCBI
4	Torre LA, Siegel RL and Jemal A: Lung Cancer Statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
5	Chu K, Gao G, Yang X, Ren S, Li Y, Wu H, Huang Y and Zhou C: MiR-512-5p induces apoptosis and inhibits glycolysis by targeting p21 in non-small cell lung cancer cells. Int J Oncol. 48:577–586. 2016. View Article : Google Scholar : PubMed/NCBI
6	Wei J, Ma Z, Li Y, Zhao B, Wang D and Jin Y and Jin Y: miR-143 inhibits cell proliferation by targeting autophagy-related 2B in non-small cell lung cancer H1299 cells. Mol Med Rep. 11:571–576. 2015. View Article : Google Scholar : PubMed/NCBI
7	Zhou YL, Xu YJ and Qiao CW: MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp Pathol. 8:6312–6322. 2015.PubMed/NCBI
8	Li X, Li M, Chen D, Shi G and Zhao H: PAQR3 inhibits proliferation via suppressing PI3K/AKT signaling pathway in non-small cell lung cancer. Arch Med Sci. 14:1289–1297. 2018. View Article : Google Scholar : PubMed/NCBI
9	Li Q, Xia S, Yin Y, Guo Y, Chen F and Jin P: miR-5591-5p regulates the effect of ADSCs in repairing diabetic wound via targeting AGEs/AGER/JNK signaling axis. Cell Death Dis. 9:5662018. View Article : Google Scholar : PubMed/NCBI
10	Xu Y, Toure F, Qu W, Lin L, Song F, Shen X, Rosario R, Garcia J, Schmidt AM and Yan SF: Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem. 285:23233–23240. 2010. View Article : Google Scholar : PubMed/NCBI
11	Chong SF, Lee JH, Zelikin AN and Caruso F: Tuning the permeability of polymer hydrogel capsules: an investigation of cross-linking density, membrane thickness, and cross-linkers. Langmuir. 27:1724–1730. 2011. View Article : Google Scholar : PubMed/NCBI
12	Bongarzone S, Savickas V, Luzi F and Gee AD: Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 60:7213–7232. 2017. View Article : Google Scholar : PubMed/NCBI
13	Jing RR, Cui M, Sun BL, Yu J and Wang HM: Tissue-specific expression profiling of receptor for advanced glycation end products and its soluble forms in esophageal and lung cancer. Genet Test Mol Biomarkers. 14:355–361. 2010. View Article : Google Scholar : PubMed/NCBI
14	Nankali M, Karimi J, Goodarzi MT, Saidijam M, Khodadadi I, Razavi AN and Rahimi F: Increased Expression of the Receptor for Advanced Glycation End-Products (RAGE) Is Associated with Advanced Breast Cancer Stage. Oncol Res Treat. 39:622–628. 2016. View Article : Google Scholar : PubMed/NCBI
15	Wang D, Li T, Ye G, Shen Z, Hu Y, Mou T, Yu J, Li S, Liu H and Li G: Overexpression of the receptor for advanced glycation endproducts (RAGE) is associated with poor prognosis in gastric cancer. PLoS One. 10:e01226972015. View Article : Google Scholar : PubMed/NCBI
16	Zheng L, Li D, Zhou YM, Yang H, Cheng D and Ma XX: Effects of receptor for advanced glycation endproducts on microvessel formation in endometrial cancer. BMC Cancer. 16:932016. View Article : Google Scholar : PubMed/NCBI
17	Zhang W, Fan J, Chen Q, Lei C, Qiao B and Liu Q: SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma. Oncol Lett. 15:7028–7036. 2018.PubMed/NCBI
18	Yang Q, Tang Y, Tang C, Cong H, Wang X, Shen X and Ju S: Diminished LINC00173 expression induced miR-182-5p accumulation promotes cell proliferation, migration and apoptosis inhibition via AGER/NF-κB pathway in non-small-cell lung cancer. Am J Transl Res. 11:4248–4262. 2019.PubMed/NCBI
19	Fu J, Khaybullin R, Liang X, Morin M, Xia A, Yeh A and Qi X: Discovery of gene regulation pattern in lung cancer by gene expression profiling using human tissues. Genom Data. 3:112–115. 2015. View Article : Google Scholar : PubMed/NCBI
20	Pan Z, Liu L, Nie W, Miggin S, Qiu F, Cao Y, Chen J, Yang B, Zhou Y, Lu J and Yang L: Long non-coding RNA AGER-1 functionally upregulates the innate immunity gene AGER and approximates its anti-tumor effect in lung cancer. Mol Carcinog. 57:305–318. 2018. View Article : Google Scholar : PubMed/NCBI
21	Serveaux-Dancer M, Jabaudon M, Creveaux I, Belville C, Blondonnet R, Gross C, Constantin JM, Blanchon L and Sapin V: Pathological implications of receptor for advanced glycation end-product (AGER) gene polymorphism. Dis Markers. 2019:20673532019. View Article : Google Scholar : PubMed/NCBI
22	Liu W, Ouyang S, Zhou Z, Wang M, Wang T, Qi Y, Zhao C, Chen K and Dai L: Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases. Mol Genet Genomic Med. 7:e005282019.PubMed/NCBI
23	Beucher J, Boelle PY, Busson PF, Muselet-Charlier C, Clement A and Corvol H; French C F Modifier Gene Study Investigators, : AGER-429T/C is associated with an increased lung disease severity in cystic fibrosis. PLoS One. 7:e419132012. View Article : Google Scholar : PubMed/NCBI
24	Caraher EJ, Kwon S, Haider SH, Crowley G, Lee A, Ebrahim M, Zhang L, Chen LC, Gordon T, Liu M, et al: Receptor for advanced glycation end-products and World Trade Center particulate induced lung function loss: A case-cohort study and murine model of acute particulate exposure. PLoS One. 12:e01843312017. View Article : Google Scholar : PubMed/NCBI
25	Machahua C, Montes-Worboys A, Planas-Cerezales L, Buendia-Flores R, Molina-Molina M and Vicens-Zygmunt V: Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis. Respir Res. 19:2152018. View Article : Google Scholar : PubMed/NCBI
26	de Bittencourt Pasquali MA, Gelain DP, Zeidan-Chulia F, Pires AS, Gasparotto J, Terra SR and Moreira JC: Vitamin A (retinol) downregulates the receptor for advanced glycation endproducts (RAGE) by oxidant-dependent activation of p38 MAPK and NF-kB in human lung cancer A549 cells. Cell Signal. 25:939–954. 2013. View Article : Google Scholar : PubMed/NCBI
27	Wei TY, Juan CC, Hisa JY, Su LJ, Lee YC, Chou HY, Chen JM, Wu YC, Chiu SC, Hsu CP, et al: Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. Cancer Sci. 103:1640–1650. 2012. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Campbell KJ and Tait SWG: Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 8(pii): 1800022018. View Article : Google Scholar : PubMed/NCBI
30	Hassan M, Watari H, AbuAlmaaty A, Ohba Y and Sakuragi N: Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014:150845. 2014. View Article : Google Scholar
31	Yu DH, Huang JY, Liu XP, Ruan XL, Chen C, Hu WD and Li S: Effects of hub genes on the clinicopathological and prognostic features of lung adenocarcinoma. Oncol Lett. 19:1203–1214. 2020.PubMed/NCBI